Serological Analysis of SEREX-Defined Medullary Breast Carcinoma-Associated Antigens

REFERENCES

• Marginean F, Rakha EA, Ho BC, Ellis IO, Lee AH. Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast. Mod Pathol 2010;23:1357–1363.
   PubMed Web of Science ®Google Scholar
• Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch 2005;447:688–694.
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10:5367–5374.
   PubMed Web of Science ®Google Scholar
• Rakha EA, El-Sayed ME, Reis-Filho J, Ellis IO. Patho-biological aspects of basal-like breast cancer. Breast Cancer Res Treat 2009;113:411–422.
   PubMed Web of Science ®Google Scholar
• Choo JR, Nielsen TO. Biomarkers for basal-like breast cancer. Cancers 2010;2(2):1040–1065.
   PubMedGoogle Scholar
• Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA 2006;295:2492–2502.
   PubMed Web of Science ®Google Scholar
• Ridolfi RL, Rosen PP, Port A, Kinne D, Miké V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977;40:1365–1385.
   PubMed Web of Science ®Google Scholar
• Wargotz ES, Silverberg SG. Medullary carcinoma of the breast: a clinicopathologic study with appraisal of current diagnostic criteria. Hum Path 1988;19:1340–1346.
   PubMed Web of Science ®Google Scholar
• Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14:1368–1376.
   PubMed Web of Science ®Google Scholar
• Guo X, Fan Y, Lang R, Gu F, Chen L, Cui L, Pringle GA, Zhang X, Fu L. Tumor infiltrating lymphocytes differ in invasive micropapillary carcinoma and medullary carcinoma of breast. Mod Path 2008;21:1101–1107.
   PubMed Web of Science ®Google Scholar
• Hsu SM, Raine L, Nayak RN. Medullary carcinoma of breast: an immunohistochemical study of its lymphoid stroma. Cancer 1981;48:1368–1376.
   PubMed Web of Science ®Google Scholar
• Kotlan B, Simsa P, Teillaud JL, Fridman WH, Toth J, McKnight M, Glassy MC. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J Immunol 2005;175:2278–2285.
   PubMed Web of Science ®Google Scholar
• Hansen MH, Nielsen H, Ditzel HJ. The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci USA 2001;98:12659–12664.
   PubMed Web of Science ®Google Scholar
• Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11810–11813.
   PubMed Web of Science ®Google Scholar
• Kiyamova R, Kostianets O, Malyuchik S, Filonenko V, Usenko V, Gurtovyy V, Khozayenko Y, Antonuk S, Old L, Gout I. Identification of tumor-associated antigens from medullary breast carcinoma by a modified SEREX approach. Mol Biotech 2010;46:105–112.
   PubMed Web of Science ®Google Scholar
• Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156–159.
   PubMed Web of Science ®Google Scholar
• Kubista M, Andrade JM, Bengtsson M, Forootan A, Jonák J, Lind K, Sindelka R, Sjöback R, Sjögreen B, Strömbom L, Ståhlberg A, Zoric N. The real-time polymerase chain reaction. Mol Aspects Med 2006;27:95–125.
   PubMedGoogle Scholar
• Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. FEBS J 2009; 276:6880–6904.
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Welt S, Gordon CM, Chen YT, Gure AO, Stockert E, Jungbluth AA, Ritter G, Jäger D, Jäger E, Knuth A, Old LJ. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res 2002;62:4041–4047.
   PubMed Web of Science ®Google Scholar
• Dolganov GM, Maser RS, Novikov A, Tosto L, Chong S, Bressan DA, Petrini JH. Human Rad50 is physically associated with human Mre11: identification of a conserved multiprotein complex implicated in recombinational DNA repair. Mol Cell Biol 1996;16:4832–4841.
   PubMed Web of Science ®Google Scholar
• Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T, Mistrik M, Aittomäki K, Blomqvist C, Heikkilä P, Lukas J, Nevanlinna H, Bartek J. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. Mol Oncol 2008;2:296–316.
   PubMed Web of Science ®Google Scholar
• Tommiska J, Seal S, Renwick A, Barfoot R, Baskcomb L, Jayatilake H, Bartkova J, Tallila J, Kaare M, Tamminen A, Heikkilä P, Evans DG, Eccles D, Aittomäki K, Blomqvist C, Bartek J, Stratton MR, Nevanlinna H, Rahman N. Evaluation of RAD50 in familial breast cancer predisposition. Int J Cancer 2006;118:2911–2916.
   PubMed Web of Science ®Google Scholar
• Yang H, Duckett CS, Lindsten T. iPABP, an inducible poly(A)-binding protein detected in activated human T cells. Mol Cell Biol 1995;15:6770–6776.
   PubMedGoogle Scholar
• Powell JA, Gardner AE, Bais AJ, Hinze SJ, Baker E, Whitmore S, Crawford J, Kochetkova M, Spendlove HE, Doggett NA, Sutherland GR, Callen DF, Kremmidiotis G. Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genes. Genomics 2002;80:303–310.
   PubMed Web of Science ®Google Scholar
• Miller BJ, Wang D, Krahe R, Wright FA. Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am J Hum Genet 2003;73:748–767.
   PubMed Web of Science ®Google Scholar
• Zhang A, Yeung PL, Li CW, Tsai SC, Dinh GK, Wu X, Li H, Chen JD. Identification of a novel family of ankyrin repeats containing cofactors for p160 nuclear receptor coactivators. J Biol Chem 2004;279:33799–33805.
   PubMed Web of Science ®Google Scholar
• Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997;277:965–968.
   PubMed Web of Science ®Google Scholar
• Goshima G, Mayer M, Zhang N, Stuurman N, Vale RD. Augmin: a protein complex required for centrosome-independent microtubule generation within the spindle. J Cell Biol 2008; 181:421–429.
   PubMed Web of Science ®Google Scholar
• Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, Burleigh A, Delaney A, Gelmon K, Guliany R, Senz J, Steidl C, Holt RA, Jones S, Sun M, Leung G, Moore R, Severson T, Taylor GA, Teschendorff AE, Tse K, Turashvili G, Varhol R, Warren RL, Watson P, Zhao Y, Caldas C, Huntsman D, Hirst M, Marra MA, Aparicio S. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809–813.
   PubMed Web of Science ®Google Scholar
• Kappes F, Burger K, Baack M, Fackelmayer FO, Gruss C. Subcellular localization of the human proto-oncogene protein DEK. J Biol Chem 2001;276:26317–22633.
   PubMed Web of Science ®Google Scholar
• Riveiro-Falkenbach E, Soengas MS. Control of tumorigenesis and chemoresistance by the DEK oncogene. Clin Cancer Res 2010;16:2932–2938.
   PubMed Web of Science ®Google Scholar
• Mor-Vaknin N, Punturieri A, Sitwala K, Faulkner N, Legendre M, Khodadoust MS, Kappes F, Ruth JH, Koch A, Glass D, Petruzzelli L, Adams BS, Markovitz DM. The DEK nuclear autoantigen is a secreted chemotactic factor. Mol Cell Biol 2006;26:9484–9496.
   PubMedGoogle Scholar
• Fiorillo AA, Medler TR, Feeney YB, Liu Y, Tommerdahl KL, Clevenger CV. HMGN2 inducibly binds a novel transactivation domain in nuclear PRLr to coordinate Stat5a-mediated transcription. Mol Endocrinol 2011;25:1550–1564.
   PubMed Web of Science ®Google Scholar
• Resto VA, Caballero OL, Buta MR, Westra WH, Wu L, Westendorf JM, Jen J, Hieter P, Sidransky D. A putative oncogenic role for MPP11 in head and neck squamous cell cancer. Cancer Res 2000;60:5529–5535.
   PubMed Web of Science ®Google Scholar
• Lu Y, Yi Y, Liu P, Wen W, James M, Wang D, You M. Common human cancer genes discovered by integrated gene-expression analysis. PloS One 2007;2:e1149. serial online: http://www.plosone. org/article/info:doi%2F10.1371%2Fjournal.pone.0001149
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Gout I, Gordon CM, Williamson B, Stockert E, Gure AO, Jäger D, Chen YT, Mackay A, O'Hare MJ, Old LJ. Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immun 2001;1:4. serial online: http://archive.cancerimmunity.org/v1p4/010202
   PubMedGoogle Scholar
• Grasemann C, Gratias S, Stephan, H, Schüler A, Schramm A, Klein-Hitpass L, Rieder H, Schneider S, Kappes F, Eggert A, Lohmann DR. Gains anoverexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. Oncogene 2005;24:6441–6449.
   PubMed Web of Science ®Google Scholar
• Kroes RA, Jastrow A, McLone MG, Yamamoto H, Colley P, Kersey DS, Yong VW, Mkrdichian E, Cerullo L, Leestma J, Moskal JR. The identification of novel therapeutic targets for the treatment of malignant brain tumors. Cancer Lett 2000;156:191–198.
   PubMedGoogle Scholar
• Khodadoust MS, Verhaegen M, Kappes F, Riveiro-Falkenbach E, Cigudosa JC, Kim DS, Chinnaiyan AM, Markovitz DM, Soengas MS. Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res 2009;69:6405–6413.
   Google Scholar
• Carro MS, Spiga FM, Quarto M, Di Ninni V, Volorio S, Alcalay M, Müller H. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle 2006;5:1202–1207.
   PubMed Web of Science ®Google Scholar
• Abba MC, Sun H, Hawkins KA, Drake JA, Hu Y, Nunez MI, Gaddis S, Shi T, Horvath S, Sahin A, Aldaz CM. Breast cancer molecular signatures as determined by SAGE: correlation with lymph node status. Mol Cancer Res 2007;881–890.
   PubMed Web of Science ®Google Scholar
• Mazzarella R, Pengue G, Yoon J, Jones J, Schlessinger D. Differential expression of XAP5, a candidate disease gene. Genomics 1997;45(1):216–219.
   PubMed Web of Science ®Google Scholar
• Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006;9:121–132.
   PubMed Web of Science ®Google Scholar
• Lilljebjörn H, Heidenblad M, Nilsson B, Lassen C, Horvat A, Heldrup J, Behrendtz M, Johansson B, Andersson A, Fioretos T. Combined high-resolution array-based comparative genomic hybridization and expression profiling of ETV6/RUNX1-positive acute lymphoblastic leukemias reveal a high incidence of cryptic Xq duplications and identify several putative target genes within the commonly gained region. Leukemia 2007;21:2137–2144.
   PubMed Web of Science ®Google Scholar
• Tanigaki K, Han H, Yamamoto N, Tashiro K, Ikegawa M, Kuroda K, Suzuki A, Nakano T, Honjo T. Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells. Nat Immun 2002;3:443–450.
   Google Scholar
• Suriano AR, Sanford AN, Kim N, Oh M, Kennedy S, Henderson MJ, Dietzmann K, Sullivan KE. GCF2/LRRFIP1 represses tumor necrosis factor alpha expression. Society 2005;25:9073–9081.
   Google Scholar
• Yang P, An H, Liu X, Wen M, Zheng Y, Rui Y, Cao X. The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. Nat Immunol 2010;11:487–494.
   PubMed Web of Science ®Google Scholar
• Wang T, Chuang TH, Ronni T, Gu S, Du YC, Cai H, Sun HQ, Yin HL, Chen X. Flightless I homolog negatively modulates the TLR pathway. J Immunol 2006;176:1355–1362.
   PubMed Web of Science ®Google Scholar
• Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ, Herbst R, Dreps A, Azam M, Rubinstein M, Natoli C, Shawverll LK, Schlessinger J, Iacobellin S. The secreted tumor-associated antigen 90 K is a potent immune stimulator. J Biol Chem. 1994;269:18401–18407.
   PubMed Web of Science ®Google Scholar
• Fukaya Y, Shimada H, Wang, L-C, Zandi E, DeClerck YA. Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. J Biol Chem 2008;283:18573–18581.
   PubMed Web of Science ®Google Scholar
• Feng Y, Huang N, Wu Q, Wang B. HMGN2: a novel antimicrobial effector molecule of human mononuclear leukocytes? J Leukoc Biol 2005;78:1136–1141.
   PubMed Web of Science ®Google Scholar
• Feng F, Wang YC, Hu XB, Liu XW, Ji G, Chen YR, Wang L, He F, Dou GR, Liang L, Zhang HW, Han H. The transcription factor RBP-J-mediated signaling is essential for dendritic cells to evoke efficient anti-tumor immune responses in mice. Mol Cancer 2010;9:90. serial online: http://www.molecular-cancer.com/content/9/1/90
   PubMedGoogle Scholar
• Utz PJ, Anderson P. Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens. Arthritis Rheum 1998;41:1152–1160.
   PubMed Web of Science ®Google Scholar